Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Daxas (roflumilast) is the first oral anti-inflammatory phosphodiesterase inhibitor (PDE-4)
for patients with severe chronic obstructive pulmonary disease (COPD) experiencing chronic
cough and sputum and with a history of exacerbations as add-on to bronchodilator treatment.
With its mode of action Daxas can reduce exacerbations rates and improve lung function
parameters which may result in a better health-related quality of life and an improved
long-term management of COPD.
The aim of this non-interventional study is to evaluate data on quality of life in COPD
patients in Germany in a real life medical setting. Evaluation is based on two COPD specific
questionnaires to assess the patient's health status over six months. During the study,
socio-demographic data and cost-of-illness data will be recorded. Daxas (tablet) will be
administered once daily. The study will provide further data on the safety and tolerability
of Daxas.